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Abstract
Previous studies in rodents have shown that after a moderate traumatic brain injury (TBI) with a 
controlled cortical impact (CCI) device, the adult-born immature granular neurons in the dentate 
gyrus are the most vulnerable cell type in the hippocampus. There is no effective approach for 
preventing immature neuron death following TBI. We found that tyrosine-related kinase B (TrkB), 
a receptor of brain-derived neurotrophic factor (BDNF), is highly expressed in adult-born 
immature neurons. We determined that the small molecule imitating BDNF, 7, 8-
dihydroxyflavone (DHF), increased phosphorylation of TrkB in immature neurons both in vitro 
and in vivo. Pre-treatment with DHF protected immature neurons from excitotoxicity-mediated 
death in vitro, and systemic administration of DHF before moderate CCI injury reduced the death 
of adult-born immature neurons in the hippocampus 24 hours following injury. By contrast, 
inhibiting BDNF signaling using the TrkB antagonist ANA12 attenuated the neuroprotective 
effects of DHF. These data indicate that DHF may be a promising chemical compound that 
promotes immature neuron survival after TBI through activation of the BDNF signaling pathway.
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INTRODUCTION
Traumatic brain injury (TBI) causes a mechanical injury that can induce a primary injury of 
the immediate tissue (1, 2), and a secondary injury of the surviving cells that is triggered by 
the primary event (1, 3). The secondary injury occurs in many brain areas, including the 
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cortex and hippocampus in both humans (4–9) and experimental animals (1, 10, 11). This 
injury contributes to further cognitive, sensory, and motor dysfunction (1, 12). Currently, 
there is no FDA-approved therapeutic treatment for these disorders that occur following 
TBI.
The hippocampus is one of the regions of the adult brain that can support neurogenesis 
throughout life, as demonstrated in rodents and primates, including humans (13–17). New 
neurons are continuously generated from neural stem/progenitor cells (NSCs) in the 
subgranular zone of the hippocampal dentate gyrus (HDG) (18, 19). These newborn neurons 
integrate into the neural circuitry and are believed to play a critical role in learning and 
memory (18–20). We previously showed that adult-born immature neurons in the HDG are 
the most vulnerable cell type to a moderate controlled cortical impact (CCI) TBI (21–23). 
Most of the neuron death occurs within 24 hours (23). Because the hippocampus is critical 
for higher cognitive function (24, 25) and is frequently associated with post-traumatic 
seizure generation (26), disturbances in hippocampal neurogenesis may play a significant 
role in the pathogenesis of TBI-related injuries. Thus, in addition to other mechanisms of 
neuroprotection, it is important to explore approaches to prevent immature neuron death 
after TBI.
One approach is to explore the use of neurotrophins that exist naturally in the brain. Brain 
derived neurotrophic factor (BDNF) is a member of the neurotrophin family of growth 
factors. BDNF is active broadly in the adult brain and is highly active in the hippocampus 
(27). It regulates diverse and important functions of neurons, i.e. helping mature (28) and 
immature neurons to survive (29–31). BDNF is the most abundant neurotrophin in the 
hippocampal formation of cortex in both adult rodents and humans (2, 32).
We found that reduction of BDNF expression in the hippocampus by conditional knockout 
resulted in exacerbated death of both immature and mature neurons after TBI (30). This 
suggested that BDNF is involved in regulating the neuronal survival in the adult brain, and 
potentially might be used to protect immature neurons from death following TBI. Although 
direct injection of BDNF into the hippocampus decreased immature neuron death in a rodent 
TBI model (unpublished data), direct injection of BDNF into the hippocampus is an invasive 
treatment. Furthermore, because BDNF is a polypeptide growth factor, direct administration 
of BDNF into the brain may also cause an immune response and a further increase in 
inflammation following TBI. Therefore, an alternative molecule that can imitate BDNF 
function and can be used non-invasively is essential. One small molecule that imitates 
BDNF is 7,8-dihydroxyflavone (DHF), which protects neurons from death (33). Treatment 
with DHF improves neurological functions in rodent models of stress (34), depression (35), 
aging (36), and Alzheimer disease (37). In this study, we tested the role of DHF in immature 
neuron survival following TBI in a pre-treatment paradigm.
MATERIALS AND METHODS
Animals
Male C57BL/6 mice (Harlan Laboratories, Indianapolis, IN) were group-housed with a 
12/12-hour light/dark cycle and had access to food and water ad libitum. They were used in 
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experiments at the age of 8 to 10 weeks. All procedures were performed under protocols 
approved by the Animal Care and Use Committee of Indiana University.
Hippocampal Cells In Vitro
Brains of C57BL/6 mice (post-natal day 0) were dissected, the meninges were removed, and 
the hippocampi were isolated. Hippocampal tissue was digested with papain, and single-
cells were collected, plated onto polylysine-coated coverslips in plates, and maintained in a 
B27 supplemented Neurobasal serum-free medium (38).
DHF Treatment In Vitro
The hippocampal cells were cultured in vitro for 5 days (day-in-vitro 5 [DIV 5]) and were 
treated with either DHF (10, 100, 500, 1,000, or 5,000 nMol/L) or dimethyl sulfoxide 
(DMSO) as control. Thirty minutes after DHF or DMSO treatment, the cells were then 
exposed to 100 μMol/L glutamate with 20 μMol/L glycine for 60 minutes to create an 
excitotoxicity model in vitro. The cells were then washed with phosphate-buffered saline 
(PBS) and cultured with a B27-supplemented Neurobasal serum-free medium in the 
incubator at 37°C.
Propidium Iodide Staining
Propidium iodide (PI) staining was performed to assess cell death at 24 hours after 
glutamate and glycine treatment (39). Briefly, PI (10 μg/mL) was applied to cell culture. 
After 30 minutes at 37°C in a humid incubator, the cells were washed briefly with PBS and 
then fixed with 2% paraformaldehyde (PFA) in PBS. Fixed cells were checked by phase 
contrast microscopy. Five random fields on each coverslip were chosen for images of both 
brightfield and PI staining. The total number of cells and the number of PI-positive cells 
were counted in each field and the percentages of PI-positive cells were calculated. 
Triplicate slides were included in each group.
TBI Model
C57BL/6 male mice (n = 131), 8 to 10 weeks old, were randomly subjected to either 
moderate CCI injury or sham surgery, as previously described (40, 41), using an 
electromagnetic model (42). Briefly, the mice were anesthetized with avertin and placed in a 
stereotaxic frame (Kopf Instruments, Tujunga, CA) prior to TBI. Using sterile procedures, 
the skin was retracted and a 4-mm craniotomy centered between the lambda and bregma 
sutures was performed. A point was identified midway between the lambda and bregma 
sutures and midway between the central suture and the temporalis muscle laterally. The 
skullcap was carefully removed without disruption of the underlying dura. Prior to the 
injury, the impacting tip was angled perpendicularly to the exposed cortical surface. The 
moderate severity brain injury was then introduced with the depth of deformation set at 1.0 
mm and the piston velocity controlled at 3.0 m/sec. Sham (non-injured) animals (n = 18) 
received the craniotomy but no CCI injury. During all surgical procedures and recovery, the 
core body temperature of the animals was maintained at 36°–37°C. Animals did not receive 
analgesics after surgery.
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DHF Administration
One hour prior to surgery, the animals received intraperitoneal injection of either DHF once 
(5 mg/kg in 17% DMSO) or vehicle (17% DMSO). Twenty-four hours after surgery, the 
animals were perfused and brains were collected for assessments.
ANA12 Administration
One hour prior to surgery, animals received an intraperitoneal injection of 0.5 mg/kg the 
tyrosine-related kinase B (TrkB) antagonist ANA12 (Fisher Science, Waltham, MA) (43, 
44). Right after ANA12 injection, the animal received another intraperitoneal injection of 
DHF (5 mg/kg in 17% DMSO) or vehicle (17% DMSO).
Tissue Processing
Animals were deeply anesthetized with an overdose of avertin and then perfused 
transcardially with 0.9% saline, followed by an ice-cold fixative containing 4% PFA in PBS. 
The brains were removed and post-fixed in 4% PFA overnight, then cryoprotected with 30% 
sucrose for 48 hours. Serial coronal sections (30 μm thick) were cut using a cryostat (Leica 
CM 1950) and stored at −20°C.
Fluoro-Jade B Staining of Dying Neurons
The staining procedures were implemented as previously described (45, 46). Briefly, the 
sections mounted on slides were incubated in 0.06% potassium permanganate for 20 
minutes, then rinsed in distilled water for 5 minutes. Thereafter, the sections were incubated 
in 0.0004% fluoro-Jade-B ([FJB], Histo-Chem, Inc., Jefferson, AR) for 20 minutes, and 
counterstained with 4′,6-diamidino-2-phenylindole ([DAPI], Sigma, St. Louis, MO) for 5 
minutes. Finally, sections were rinsed in distilled water and air-dried overnight. The dry 
slides were mounted with DPX (Fluka).
Hippocampal Neuron Death Assessment
To determine the FJB-positive cell density across the entire hippocampus, 1 out of every 6 
sections throughout the entire extent of the hippocampal formation was selected for 
assessment. The anatomical boundaries of each hippocampal subregion (CA1; CA3; 
granular cell layer [GCL]; molecular layer; hilus) were identified as previously described 
(47). The number of FJB-positive neurons in each subregion was determined by a blinded 
quantitative histological analysis through the Z-axis under a microscope system (Zeiss 
Axiovert 200 M, Carl Zeiss MicroImaging, Inc., Thornwood, NY), with a 40X objective. 
The subregion area (μm2) was measured with imaging software (AxioVision, v4.0, Carl 
Zeiss MicroImaging, Inc.). The results of FJB-positive cell density were calculated with the 
section thickness (30 μm) and presented as N/mm3.
Immunohistochemistry
Tissue sections were rinsed with PBS and then blocked with 10% donkey serum in PBS with 
0.3% Triton for 2 hours at 4°C. The primary antibodies were sheep-anti-mouse p-TrkB 
(phospho Y816), (ab74841, Abcam, Cambridge, MA), diluted 1:20, mouse-anti-mouse 
NeuN, (MAB377, Millipore, Billerica, MA), diluted 1:100, and guinea pig-anti-mouse 
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doublecortin (Dcx) (ab2253, Millipore) diluted 1:1000. The antibodies were applied and the 
sections incubated for 48 hours at 4°C. After they were rinsed with PBS, the sections were 
incubated with the appropriate secondary antibody (all from Invitrogen) for 1 hour at 4°C. 
The antibodies were donkey-anti-sheep Alexa488 IgG, 1:1000, (A11015), in 10% donkey 
serum in PBS, goat-anti-mouse cy3 IgG, 1:400, (A10521), or goat-anti-guinea pig cy5 IgG, 
1:200, (A21450) in blocking buffer (1% bovine serum albumin, 5% normal goat serum in 
PBS). After rinsing, the sections were counterstained with DAPI for 2 minutes, rinsed with 
PBS, and then briefly with water. They were then mounted on slides with the mounting 
medium. Images were taken by using a Zeiss microscope.
Western Blot
Hippocampi of all groups (n = 3 mice/group) were dissected and protein samples were 
prepared for the Western blot. Equal amounts of protein were loaded into the wells of the 
SDS-PAGE gel, along with molecular weight markers. The gels were then run for 1 to 2 
hours at 100V. Afterward, the proteins were transferred from the gel to the membrane and 
were incubated overnight. For antibody staining, the membrane was blocked for 1 hour at 
room temperature using 5% blocking solution. Then the membrane was incubated with 
appropriate dilutions of the above-described primary antibody overnight at 4°C. After 
washing in Tris-buffered saline with Tween (TBST) 3 times, the membrane was incubated 
with the recommended dilution of labeled secondary antibody for 1 hour at room 
temperature. The membrane was washed 3 times and rinsed in TBST. Finally, images were 
acquired using normal image scanning methods for colorimetric detection.
Statistical Analyses
All data are presented as mean ± SE, with the number of repetitive experiments or mice 
indicated. Data of different groups were statistically compared using one-way ANOVA or 
two-way ANOVA followed by post hoc tests.
RESULTS
DHF Protects Immature Hippocampal Neurons from Excitotoxic Injury In Vitro
Following experimental TBI, the interstitial concentration of glutamate may increase to a 
more than 100-fold higher than the normal level; glutamate-mediated excitotoxicity is well 
documented and leads to cell death right after injury (48). To imitate in vivo traumatic injury 
of immature neurons, hippocampi at neonatal day 0 were dissected, dissociated into single 
cells, and cultured in vitro. At DIV5, we assessed the cell types of the cultured cells using 
double immunostaining with an antibody against nestin, a marker for neural progenitors, and 
an antibody against Dcx, a marker for newborn neurons (49). Nine percent of the cells 
expressed only Nestin, 25% of the cells expressed both Nestin and Dcx, and 44% of the cells 
expressed only Dcx (Supplemental Fig. 1). These results indicated that 69% of the cells are 
either new neurons or are differentiating into new neurons at DIV 5 (50).
To assess the effect of DHF on neuronal survival following the glutamate/glycine-induced 
injury, the cells were pretreated with DHF in DMSO in a concentration of 500 nM or DMSO 
without DHF for 30 minutes before 1-hour exposure to glutamate (100 μM) and glycine (20 
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μM) to induce excitotoxicity. Twenty-four hours later, PI staining was performed to detect 
dead cells (Fig. 1a). In the vehicle (DMSO)-treated group there were 6% ± 1% of neurons 
labeled by PI (Fig. 1b–d, n). Glutamate/glycine treatment caused massive neuronal death 
(47% ± 3%, p < 0.001 vs. vehicle group; Fig. 1e–g, n). DHF treatment significantly reduced 
the PI-positive cells to 20% ± 1%, suggesting that DHF protected neurons from death 
induced by glutamate/glycine (Fig. 1h–j, n, p < 0.001 vs. glutamate/glycine treatment 
group). DHF treatment alone did not significantly affect the death (7% ± 1%) of healthy 
neurons without glutamate/glycine treatment (Fig. 1k–m, n). These results indicate that DHF 
protects neurons from death induced by glutamate/glycine-mediated excitotoxicity in vitro.
To determine an optimal dose of DHF for neuroprotection, the neurons from hippocampi 
(post-natal day 0) at DIV 5 were incubated with different concentrations of DHF from 0 to 
5,000 nM 30 minutes before glutamate/glycine treatment (Fig. 1o). Twenty-four hours after 
glutamate/glycine treatment, PI staining was performed to detect the dead neurons. Cell 
death was induced by glutamate/glycine-mediated excitotoxicity without DHF treatment. 
When the cells were treated with DHF at a very low concentration of 10 nM, the cell 
glutamate/glycine-induced cell death was significantly reduced to 37% ± 1%, indicating that 
DHF showed a neuroprotective effect at the low concentration (p < 0.01). The 
neuroprotective effect of DHF was exhibited in a dose-dependent manner (Fig. 1o). The rate 
of cell death induced by glutamate/glycine-mediated excitotoxicity decreased to 23% ± 3% 
when treated with DHF at a concentration of 100 nM (F = 62.834, p < 0.001), and to 17% ± 
2% at 500 nM (p < 0.05 vs. DHF at a concentration of 100nM). The neuroprotective effect 
reached a plateau after a concentration of 500 nM. The rate of cell death was 14% ± 2% 
when treated with DHF at a concentration of 1,000 nM, and was 13% ± 1% at 5,000 nm. 
The increase in DHF concentration to more than 500 nM did not further reduce the rate of 
cell death, suggesting that 500 nM is an optimal concentration for neuroprotection in vitro.
DHF Treatment Reduced Neuron Death in the Hippocampus After TBI
TBI abruptly induces cell death, neuronal dysfunction, vascular damage, and glial 
reactivation (51). Cell death in the hippocampus following CCI peaks at 24 hours, drops 
sharply to a low level at 48 hours, and then maintains a minimal level for up to 2 weeks after 
TBI (23).
We assessed whether DHF can protect neurons from death in the hippocampus following 
TBI. One hour before inducing TBI, we administered DHF (5 mg/kg, i.p. injection) or 
DMSO as control. The DHF dose has been shown to protect neurons from apoptotic cell 
death (33). The mice were perfused 24 hours after TBI to evaluate cell death with FJB 
staining (52, 53). Although we did not observe any FJB-positive cells in the HDG of sham 
operated mice (Fig. 2 a), we observed a large number of FJB-positive dying neurons mainly 
located in the HDG of TBI-injured mice (Fig. 2b–d), which confirmed our prior report (23). 
Further quantification of FJB-positive cells in the HDG showed there were 25395 ± 
1260/mm3 FJB-positive cells in the HDG of mice that received only a TBI (Fig. 2b). The 
number of FJB-positive cells was reduced to 19505 ± 600/mm3 in TBI-injured mice with 
DHF treatment (Fig. 2c), which is a 23.19% reduction in cell death; this was statistically 
significant (Fig. 2e, F=7.123, p < 0.01). In contrast, in TBI injury mice with DMSO 
Chen et al. Page 6
J Neuropathol Exp Neurol. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
treatment, the number of FJB-positive cells in the HDG (25426 ± 1717/mm3) was not 
different from the untreated TBI group (Fig. 2d). These data indicated that DHF treatment 
can protect neurons in the HDG from death following TBI.
DHF Treatment Protects Immature Neurons From Death in the Hippocampus After TBI
We next assessed whether protecting cell death in the HDG with pre-injury DHF increases 
the number of immature neurons in this area after TBI using immunostaining with anti-Dcx 
antibody, a specific marker for newborn immature neurons (49). Immature neurons stained 
red by Dcx located in the inner one third of the GCL (Fig. 3a). In sham-operated mice there 
were 187±14 Dcx-positive immature neurons in the hippocampus (Fig. 3a, e). In tissue from 
mice that received only a TBI, the number of Dcx-positive cells was reduced to 76 ± 4 (Fig. 
3b, e). Between the 2 groups, the reduction seen in the number of immature neurons at the 
epicenter sections was 59.36% within 24 hours after TBI (p < 0.001), confirming previous 
results (21).
The number of Dcx-positive immature neurons increased (142 ± 9) in the epicenter sections 
from TBI-injured mice with DHF pre-treatment, as compared to TBI-injured mice with 
DMSO (control) treatment (Fig. 3c, e, p < 0.01). After DHF treatment, only 24% of 
immature neurons were induced to death by TBI, indicating a 59.46% protection rate. In 
contrast, in the control group, DMSO treatment did not significantly change the number of 
newborn neurons (82 ± 3) following TBI (Fig. 3d, e). These data indicate that DHF 
effectively protects immature neurons from death following TBI.
TrkB Phosphorylation Is Reduced in the HDG Following TBI and DHF Treatment Restored 
TrkB Phosphorylation
Brain-derived neurotrophic factor and its receptor TrkB are broadly expressed in the 
developing and adult mammalian brain (54). TrkB tyrosine autophosphorylation in response 
to BDNF stimulates intracellular signaling that is critical for neuronal survival, 
morphogenesis, and plasticity. The level of phosphorylated TrkB (p-TrkB) is used as an 
indicator for the activity of BDNF signaling (55). We evaluated the total TrkB and p-TrkB 
level in the hippocampus 24 hours after TBI with Western blot and found that the level of 
phosphorylated TrkB was reduced after injury, although the total protein level of TrkB was 
not obviously changed (Fig. 4a). DHF treatment increased p-TrkB level in the hippocampus 
(Fig. 4a). Treatment with ANA12, which can specifically inhibit the phosphorylation of the 
TrkB receptors by occupying the binding site shared with BDNF and DHF (56), attenuated 
DHF-induced TrkB phosphorylation (Fig. 4a). These results suggest that the BDNF 
signaling activity is impacted by TBI and that DHF restored it through activating its receptor 
TrkB.
Immunostaining with antibody to evaluate the distribution and protein level of p-TrkB in the 
HDG showed that TrkB is highly phosphorylated in the sham-operated hippocampus, 
mainly in the neurons located in the inner one third of the GCL, where the newborn neurons 
reside (Fig. 4b). TBI markedly reduced the intensity of p-TrkB immunoreactivity in the 
hippocampus (Fig. 4c). The immunostaining of p-TrkB in the inner one third of the GCL of 
TBI-injured mice was significantly reduced compared to the mice with sham operation. 
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DHF treatment significantly increased p-TrkB in the hippocampus, particularly those 
neurons in the inner one third of the GCL (Fig. 4d). Treatment with ANA12 attenuated 
DHF-induced p-TrkB in the inner one third of the GCL following TBI (Fig. 4e, f). These 
results provide further evidence that DHF restored BDNF signaling through activating its 
receptor TrkB in the hippocampus following TBI.
DHF Pretreatment Restored TrkB Phosphorylation in Immature Neurons in the HDG 
Following TBI
Because the distribution of p-TrkB is highly correlated with the location of immature 
neurons in the hippocampus, we next determined the effect of p-TrkB in newborn neurons 
following TBI by double immunostaining with antibodies against Dcx and p-TrkB. As 
shown in Figure 4b, p-TrkB is highly phosphorylated in the neurons at the inner GCL (Fig. 
5a). The p-TrkB is highly expressed in Dcx-positive immature neurons (Fig. 5b–d), 
indicating that BDNF is relatively more active in the immature neurons than other mature 
neurons in the hippocampal GCL. After TBI, the strong fluorescence of p-TrkB in the inner 
GCL was diminished. The Dcx-positive cells were significantly reduced in the HDG 
following TBI (Fig. 5e). Expression of p-TrkB in the spared immature neurons became 
difficult to detect (Fig. 5f–h). These data indicate that TBI not only induces immature 
neuron death but also significantly reduces the activity of BDNF signaling in the newborn 
neurons. In contrast, in the CCI-injured mice treated with DHF, p-TrkB was extensively 
expressed in the HDG, i.e. p-TrkB was not only observed in the inner GCL, it was strongly 
expressed in both inner and outer granular cell layers (Fig. 5i). These results indicate that 
DHF treatment activated the BDNF signaling pathway in both immature and mature 
granular neurons in the hippocampus following TBI. When BDNF signaling is activated by 
DHF, the numbers of immature neurons were also increased (Fig. 3e, 5j–l). Treatment with 
ANA12 attenuated the protective effect of DHF on immature neuronal survival and on DHF-
induced p-TrkB in immature neurons following TBI (Fig. 5m–p). These data suggest that 
DHF treatment activates the BDNF signaling pathway and protects immature neurons from 
death triggered by TBI.
Blocking BDNF Signaling Attenuated DHF-mediated Neuroprotection In Vitro and In Vivo
To determine whether DHF plays a neuroprotective role through activating TrkB receptors, 
we blocked the activity of BDNF signaling with ANA12. We first applied ANA12 before 
the administration of DHF to inhibit the TrkB activating effect of DHF on hippocampal 
immature neurons in vitro. Consistent with the experiments above (Fig. 1n), DHF protected 
neurons from death induced by glutamate/glycine-mediated excitotoxicity in vitro (Fig. 6a, F 
= 80.30, p < 0.001). In contrast, ANA12 reduced the protective effect of DHF, suggesting 
that DHF mediated neuroprotective functions through activating the BDNF signaling 
pathway in vitro (Fig. 6a, F = 6.215, p < 0.05). ANA12 is stable in body fluids and can cross 
through the blood-brain barrier (BBB). Inhibition of TrkB phosphorylation by ANA12 
reduced the protective effect of DHF on newborn immature neurons following CCI (Fig. 6b, 
F = 20.401, p < 0.001). It also attenuated the neuroprotective effect of DHF on cell death 
(Fig. 6c–f). The density of dead cells in the GCL was 19505 ± 600/mm3 in the TBI-injured 
mice treated with DHF; in mice treated with both DHF and ANA12, the density of dead 
cells in the GCL was increased to 24776 ± 1237/mm3 (p < 0.01). This number of dead cells 
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was similar to that in TBI-injured mice without treatment (p > 0.05) (Fig. 6f). These data 
indicate that DHF exerts the neuroprotection mainly through activating the TrkB signaling-
mediated BDNF signaling pathway following TBI.
DISCUSSION
Despite advances in research and improved neurological intensive care in recent years there 
is still a lack of effective pharmacological approaches that aim to protect neurons from death 
following TBI. The discovery of NSCs in the adult brain raises a potentially promising 
strategy for repairing CNS injury. However, we recently found that newborn neurons are 
particularly vulnerable to TBI. Thus, although TBI transiently enhances NSC proliferation, 
it does not result in an increase in neurogenesis. DHF is a small molecule (MW = 254.25 g/
mol) with the ability to penetrate through the BBB and reach the brain areas that are affected 
by TBI (57). Administration of DHF can upregulate the phosphorylation of TrkB and protect 
newborn neurons from death in vitro and in vivo.
A large body of work has demonstrated the pro-survival role of BDNF in CNS neurons (58), 
including those in the cortex (28) and the hippocampus (59). In particular, BDNF is reported 
to show a pro-survival effect on immature neurons in the developing neurons (29). BDNF is 
the most abundant neurotrophin in the hippocampal formation of both the adult rodent 
cortex and human cortex (2, 32). BDNF has been shown to relate to functional recovery 
following ischemia (60).
TBI has been shown both to increase BDNF expression in the hippocampus (61–63), and to 
decrease BDNF expression in the cortex (64), suggesting that BDNF might be involved in 
modulating neurological function following TBI. Prior work has shown that there is a 
correlation between neurotrophic factor expression and outcomes in children with severe 
TBI (65). Recently, studies with TBI animal models demonstrated that increased BDNF 
might increase neurogenesis in the adult hippocampus (66), and contribute to functional 
recovery in brain injured rats with treatment of erythropoietin (67) or statins (66). D-
amphetamine treatment or voluntary exercise also improved cognitive functions and 
increased levels of BDNF in the hippocampus after TBI (68). Dietary omega-3 fatty acids or 
curcumin (69), voluntary exercise (70), intravenous administration or intracerebral 
transplantation of marrow stromal cells (71), simvastatin (66), and erythropoietin (72) 
improved recovery from TBI with upregulation of BDNF or even seemed to require BDNF. 
We found that conditional knockout of BDNF in the hippocampus further increased the cell 
death of immature and mature neurons in the hippocampus following TBI (30), indicating 
that BDNF is involved in regulating neuronal survival following TBI. This strongly suggests 
that BDNF signaling is a promising target for promoting the survival of the immature 
neurons after TBI. The above reports support the speculation that BDNF-TrkB signaling is 
involved in the process and later outcomes of TBI.
Some groups have shown that with continuous infusion of BDNF to injured areas of cortical 
or hippocampal areas, AAV-assisted transfer of TrkB gene or their combination neither 
saved neuron death in the cortex, CA3, and hilus, nor helped cognitive recovery after TBI 
(73, 74). Neither study showed a protective effect on the mature neurons against cell death 
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in cortex and the hippocampal CA3 and hilus area. Therefore, the effects of BDNF on 
recovery in learning memory and cognitive functions following TBI are still controversial.
When we investigated the activity of BDNF signaling, instead of BDNF expression, by 
assessing both TrKB expression and TrkB phosphorylation in the hippocampus following 
TBI, we found that TBI significantly reduced TrkB phosphorylation in the hippocampus by 
Western blot. Further immunostaining analyses confirmed that the level of TrkB 
phosphorylation was significantly reduced (Fig. 4), particularly in the inner GCL (Fig. 4c) 
and in newborn immature neurons (Fig. 5). This result indicates that TBI attenuates BDNF 
signaling in the hippocampus. It may partially explain, in the previous studies, moderate 
level of BDNF increase following TBI was not enough to affectively protect neurons from 
death following TBI, i.e. suggesting that stronger activation of the TrK receptor is required.
DHF is 8 times more potent in activating the BDNF pathway than BDNF itself (33). 
Although by Western blot DHF treatment significantly increased TrkB phosphorylation. 
Western blot cannot distinguish whether DHF treatment increases TrkB phosphorylation in 
the immature neurons, mature neurons, or both in the hippocampus. Based on the location 
and cell-type specific marker, we found that DHF treatment increased TrkB phosphorylation 
in both immature neurons and mature neurons in the hippocampus. It also reduced 
glutamate/glycine-induced cell excitotoxicity in newborn neuron-enriched cultures in vitro 
and systemic administration attenuated newborn neuron death and preserved newborn 
neurons in the adult hippocampus following TBI. DHF can penetrate the BBB, bind the 
extracellular domain of TrkB, and provoke its dimerization and autophosphorylation and has 
shown neuroprotective effects in several neurodegenerative disease models (33, 75).
No specific pharmacological therapy is currently available that prevents the adult born 
immature neuron death following TBI. In the present study, pre-treatment of DHF was 
proven to have the protective effect against the newborn neuronal death after TBI via 
activating the TrkB in the hippocampus. Since the pretreatment paradigm is not relevant to 
clinical application, it is important to assess whether post-injury treatment of DHF is also 
neuroprotective against newborn neuron death.
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Figure 1. 
7, 8-Dihydroxyflavone (DHF) protects immature hippocampal neurons from excitotoxic 
injury in vitro. (a) Experimental procedures. (b) Brightfield image of hippocampal granular 
neurons at the sixth day-in-vitro (DIV 6) treated with dimethyl sulfoxide (DMSO) as a 
control. (c) Propidium iodide (PI) staining to detect the dead cells. (d) Merged image of b 
and c. (e) Brightfield image of hippocampal granular neurons at DIV 6 treated with 
glutamate (Glu) (100 μM), glycine (Gly) (20 μM), and DMSO for 1 hour. (f) PI staining to 
detect the dead cells. (g) Merged image of e and f. (h) Brightfield image of hippocampal 
granular neurons at DIV 6 pretreated with DHF (500 nM) before treating with glutamate 
(100 μM), glycine (20 μM) for 1 hour. (i) PI staining to detect dead cells 25 hours after DHF 
treatment. (j) Merged image of h and i. (k) Brightfield image of hippocampal granular 
neurons at DIV 6 treated with DHF (500 nM). (l) PI staining to detect the dead cells 25 
hours after treatment. (m) Merged image of k and l. (n) Quantification of PI-positive cells at 
different treatment conditions. o: Dose-response curve of DHF on neuroprotection. (%): 
Percentage of PI-positive cells of total number of cells. *p < 0.05; **p < 0.01; ***p < 0.001. 
N.S., not significant.
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Figure 2. 
Systemic administration of 7, 8-dihydroxyflavone (DHF) reduced neuron death in 
hippocampus after subsequent traumatic brain injury (TBI). (a) Brain sections containing 
hippocampus from sham operated mice with Fluoro-Jade B (FJB) and 4′,6-diamidino-2-
phenylindole (DAPI) staining (blue). No FJB-positive cells were detected in sham-operated 
mice. (b) FJB staining (green) to detect the dying cells in the hippocampus 24 hours after 
moderate TBI. The section was counterstained with DAPI (blue). (c) FJB staining (green) to 
detect the dying cells in the hippocampus 24 hours after moderate TBI and treated with 
DHF. The section was counterstained with DAPI (blue). (d) FJB staining (green) to detect 
the dying cells in the hippocampus 24 hours after moderate TBI and treated with DMSO as a 
control. The section was counterstained with DAPI (blue). (e) Quantification of FJB-positive 
cells in the different regions of the hippocampus with different treatments. (n = 5/group, **p 
< 0.01).
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Figure 3. 
7, 8-Dihydroxyflavone (DHF) treatment increases the number of immature neurons in 
hippocampus after subsequent traumatic brain injury (TBI). (a–d) Immunostaining with 
antibody against Doublecortin (Dcx, red) to show newborn neurons in the hippocampal 
dentate gyrus of a sham operated mouse (a), a TBI mouse 24 hours after surgery (b), a TBI-
injured mouse 24 hours after receiving DHF treatment (c), or a TBI-injured mouse 24 hours 
after receiving DMSO treatment as a control (d). Sections were counterstained with 4′,6-
diamidino-2-phenylindole (DAPI) (blue). (e) Quantifications of Dcx-positive newborn 
neurons after various treatments. (n = 5/group; *p < 0.05; **p < 0.01; ***p < 0.001)
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Figure 4. 
Phosphorylation of tyrosine-related kinase B (TrkB) receptor in the hippocampus following 
traumatic brain injury (TBI). (a) Western blot to assess the phosphorylated and un-
phosphorylated TrkB receptor in the hippocampus. (b) Immunostaining to detect the 
phosphorylated TrkB receptor (p-TrkB) (green) in the hippocampus of mice 24 hours after 
sham operation. The section was counterstained with DAPI (blue). (c) Immunostaining to 
detect p-TrkB receptor (green) in the hippocampus of a mouse 24 hours after moderate TBI. 
The section was counterstained with DAPI (blue). (d) Immunostaining to detect the p-TrkB 
receptor (green) in the hippocampus of mice 24 hours after moderate TBI and 7, 8-
dihydroxyflavone (DHF) treatment. The section was counterstained with DAPI (blue). (e) 
Immunostaining to detect the p-TrkB receptor (green) in the hippocampus of a mouse 24 
hours after moderate TBI and treatment with ANA12. The section was counterstained with 
DAPI (blue). (f) Immunostaining to detect the p-TrkB receptor (green) in the hippocampus 
of mice 24 hours after moderate TBI and treated with DHF and ANA12. The section was 
counterstained with DAPI (blue).
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Figure 5. 
7, 8-Dihydroxyflavone (DHF) pre-treatment restored tyrosine-related kinase B (TrkB) 
phosphorylation in immature neurons in the hippocampal dentate gyrus after traumatic brain 
injury (TBI). (a–p) Double immunostaining to assess the expression of phosphorylated TrkB 
(p-TrkB) receptor in the newborn neurons with antibodies against p-TrkB (Green) and 
doublecortin (Dcx, red) in the hippocampal dentate gyrus at 24 hours after sham treatment 
(a), TBI (e), TBI and treated with DHF (i), and TBI and treated with DHF and ANA12 (m). 
Sections were counterstained with DAPI. Amplified images from the boxes in panels (a, e, i, 
m) show the expression of p-TrkB in the dentate gyrus (b, f j, n). Enlarged images from the 
boxes in panels (a, e, I, m) show immature neurons expressing Dcx (c, g, k, o). Merged 
images (d, h, i, p) of (b) and (c), (f) and (g), (j) and (k), and (n) and (o), respectively.
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Figure 6. 
Blocking brain derived neurotrophic factor (BDNF) signaling attenuates 7, 8-
dihydroxyflavone (DHF)-mediated neuroprotection in vitro and in vivo. (a) Quantification 
show that treatment with ANA12 attenuated 7, 8-dihydroxyflavone (DHF)-mediated 
neuroprotection in vitro, assessed with PI staining (n = 3/group, p < 0.05). (b) 
Quantifications show that ANA12 treatment attenuated DHF-mediated neuroprotection in 
vivo using immunostaining with antibody against doublecortin (Dcx) (n = 5/group, p < 
0.05). (c) Fluoro-Jade B (FJB) staining (green) demonstrates dead cells in the hippocampus 
24 hours after moderate traumatic brain injury (TBI). (d) FJB staining shows dead cells in 
the hippocampus 24 hours after moderate TBI pre-treated with DHF. (e) FJB staining shows 
dead cells in the hippocampus 24 hours after moderate TBI and pre-treated with DHF and 
ANA12. (f) Quantifications show that ANA12 treatment attenuated DHF-mediated 
neuroprotection in vivo (n = 5/group, *p < 0.05; **p < 0.01; ***p < 0.001). Sections b, c, d 
were counterstained with DAPI (blue).
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